StonvexLoading…
StonvexStonvexStonvexCore line items from MEDP's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $2.53B | $2.11B | $1.89B | $1.46B |
Operating Income | $534.93M | $446.87M | $336.82M | $278.70M |
Net Income | $451.12M | $404.39M | $282.81M | $245.37M |
EPS (Diluted) | $15.28 | $12.63 | $8.88 | $7.28 |
Total Assets | $1.98B | $2.10B | $1.66B | $1.35B |
Total Liabilities | $1.52B | $1.28B | $1.10B | $966.11M |
Cash & Equivalents | $497.05M | $669.44M | $245.45M | $28.27M |
Free Cash Flow OCF − CapEx | $681.87M | $572.27M | $396.73M | $351.17M |
Shares Outstanding | 28.37M | 30.63M | 30.75M | 31.09M |